Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-11-02

Clinical Trial Update: A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment [Phase 2]

View source ↗

Summary

Clinical trial update on Aleglitazar in patients with type 2 diabetes and moderate renal impairment. The Phase 2 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Aleglitazar (Aleglitazar)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: COMPLETED